



FY 2025 Q3

Earnings Presentation



Disclosures

Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company’s potential cash generation performance in any way.

Forward Looking Statements

This presentation includes forward-looking statements (within the meaning of applicable securities laws) to provide prospective investors with information pertaining to the Company’s long-term business objective. Forward-looking statements often, but not always, are identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeting” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, or “might” occur or be achieved and other similar expressions.

Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation.

The forward-looking statements that are contained in this presentation involve a number of risks and uncertainties and are based on certain assumptions, including but not limited to: the progress, timing and costs related to the execution of the Company’s business plan and strategy; estimates and projections regarding the industry in which the Company operates; the future success of research and development activities; the absence of material changes in general business and economic conditions; estimates regarding the future financing and capital requirements; and the absence of adverse changes in relevant laws and regulations. As a consequence, actual results might differ materially from results forecast or suggested in these forward-looking statements. Please see the Company’s most recent Annual Information Form, which is available under the Company’s profile on EDGAR at www.sec.gov/edgar and SEDAR+ at www.sedarplus.ca for additional related risks factors that could materially affect the Company’s operations and financial results.

Furthermore, forward-looking statements contained herein are made as of the date of this MD&A presentation and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise accept as required by applicable securities. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.



Fiscal Year 2025 Q3 Business Update

Corporate Update

Capital raise and financial strategy

Capital raise

\$8.8 Million (USD)

- Raised through our At-The-Market (ATM) facility
- Use of ATM approved at board level with effective execution by our bank, ClearStreet.



Cash balance at close of Q3 2025

\$12.9 million (CAD)

Extending runway significantly and offsetting short-term financing risk



Corporate Update

Commitment to financial discipline

Maintained position during sector downturn

Proactive strategy

- Streamline structure
- Introduce new leadership
- Preparation to roll out a series of strategic initiatives

Corporate Update

Leadership expansion

Dr. Kamil Isaev joins board

Experience in AI,
semiconductor technologies,
and global R&D operations

Joe Scheffler

Interim Chief Financial Officer



Boston team expansion

Dr. Li Hui

Sr. Director, Client Relations
– Over 15 years experience
in antibody development.

Corporate Update

Strategic partnership with global bioscience leader

\$8-10M (USD) Next-Gen Cancer Therapeutic Partnership

- Multi-billion-dollar bioscience company
- All-cash contract- initial \$8M purchase order issued



Pipeline update

GLP-1 manufacturing initiated to support preclinical development

- AI-designed program

Corporate Update

Technology advancements

De novo antibody design:

- Large pharma partner initiated a de novo program

Vultr partnership:

- Building out scalable cloud infrastructure
- Detailed case study, now available on presentations section of our Investor Relations website.

AWS Marketplace integration and expansion:

- December 2024 - submitted our technical review
- February 2025 - positive feedback on the DevOps segment, we are addressing minor recommendations
- Next steps- invoicing strategy

Corporate Update

Divestiture initiative update

Process has progressed



Two European wet labs

- Utrecht
- Oss, the Netherlands



Strategic Development

Unified rebrand underway


- Bringing all IPA entities under a single brand.
- Enhancing global visibility
- Building stronger platform for commercial growth



Fiscal Year 2025 Q3 Financial Update




Quarterly Revenue




All values listed in CAD.

BioStrand Revenue Growth (FY22-FY25 YTD)



All values listed in CAD.


Focus on growth through R&D and Sales & Marketing



All values listed in CAD.


Net loss of \$21.5M, equivalent to (\$0.66) per share (basic & diluted)

Net loss pre-impairment, net of tax \$2.9M, equivalent to (\$0.09) per share (basic & diluted)



All values listed in CAD.

Ending Quarterly Cash Balance of \$13M



All values listed in CAD.

Q&A

FY 2025 Q3 Earnings Call



March 28, 2024 | ir.ipatherapeutics.com | NASDAQ: IPA TSXV: IPA

©2025 Immunoprecise Antibodies LTD. All rights reserved. IPA is a trademark of Immunoprecise Antibodies LTD. BioStrand is an independently operating subsidiary of Immunoprecise Antibodies. BioStrand, LENS[®] and HYFTs are trademarks of BioStrand, BV. Talem is an independently operating subsidiary of Immunoprecise Antibodies. Talem is a trademark of Talem Therapeutics LLC.

The HUB of
Biotherapeutic
Intelligence[™]